When UVR interacts with skin, it produces photochemical changes in DNA that can adversely affect the skin's bio logical activities and produce disease. Two lesions most commonly result from UVR exposure: cyclobutane pyrimidine dimers (CPDs), in which adjacent pyrimidine rings are coupled through carbon-carbon double bonds at the 5 and 6 positions, and 6,4-pyrimidine pyrimidone photoproducts, in which adjacent pyrimidines are connected through a single bond between the 6 position of one molecule and the 4 position of the other. These alterations, if not restored to their original state, produce mutations that can ultimately lead to non melanoma skin cancers (NMSCs), including both squamous cell (SCCs) and basal cell carcinomas (BCCs) (Cleaver and Crowley, 2002) . Fortunately, virtually all living organisms possess intricate repair mechanisms to mend damaged DNA. Bulky lesions such as CPDs are normally repaired by nucleotide excision repair, but they can also be restored by base excision repair (BER). Humans, however, can repair CPDs only through nucleotide excision repair (NER). Although human cells have most of the enzymes necessary to complete BER, they lack an important DNA glycosylase required to initiate the process (Cafardi and Elmets, 2008) . The importance of DNA repair for protection from UV-induced skin cancers is evident if one examines individuals who suffer from xeroderma pigmentosum (XP), an inherited disease in which the NER pathway of DNA is deficient. These patients have a propensity to develop extensive photodamage, cutaneous SCCs, BCCs, and melanomas at an unusually early age.
Even in healthy individuals NMSCs are particularly common. In the United States alone, the estimated 1.5-3.5 million new NMSC diagnoses each year exceed those of all other types of cancer combined. Although rarely lethal, these lesions are locally destructive and the cost of their removal represents an economic burden to the healthcare system. The direct cost for treatment of NMSCs in the United States was estimated to be $1.5 billion in 2004, and if actinic keratoses-premalignant lesions that may progress to SCCs-were included, the direct cost would increase to over $2.3 billion (Bickers et al., 2006) . In contrast to most other malignancies, in which the incidence has stabilized or declined, the rate of NMSCs continues to rise (Athas et al., 2003; Karagas et al., 1999) . Moreover, in a population-based retrospective study from 1976 to 2003, the incidence of BCCs and SCCs in patients under 40 years old was found to be increasing significantly (Christenson et al., 2005) .
Efforts to prevent actinic keratoses and NMSCs have been directed at counseling patients to limit the amount of UVR that reaches the skin, either through avoidance of sun exposure and tanning bed use or through the application of sunscreens. The American Academy of Dermatology, the American Cancer Society, and other organizations throughout the world have developed sophisticated educational materials to inform the public of the deleterious effects of excessive UVR exposure and how to prevent them. Unfortunately, these campaigns have met with varying degrees of success.
Chemoprevention, the prevention of cancer through dietary manipulation or pharmacological intervention, represents an alternative to sun avoidance and the application of sunscreens for inhibiting skin cancer. Because chemopreventive agents are administered chronically to healthy individuals, emphasis must be placed not only on efficacy but also on the absence of serious side effects. The ideal chemopreventive agent would be characterized by (i) little or no toxicity, (ii) high efficacy, (iii) easy administration, (iv) a known mechanism of action, and (v) acceptance of its use by individuals at risk for cancer. Preclinical and clinical evaluations of chemoprevention drugs differ substantially from those of chemotherapeutic agents (Mukhtar and Agarwal, 1996) .
Drugs that target DNA damage or its repair fulfill many of the criteria of the ideal chemopreventive agent, and they have attracted particular attention. For example, the bacteriophage T4 pyrimidine dimer-specific DNA glycosylase (T4-PDG), also known as T4 endonuclease V (T4N5), enhances DNA repair and reduces the frequency of UV-induced mutations in epidermal keratinocytes. Liposome-encapsulated T4N5 applied to human skin in vivo can be detected in keratinocytes, where it initiates repair of UV-induced DNA damage through BER. In a phase II clinical trial, patients with XP treated with liposome-encapsulated T4N5 for one year showed a marked reduction in actinic keratoses and BCCs as compared with those treated with placebo (Yarosh et al., 2001) . As mentioned previously, patients with XP have a defect in DNA repair, unlike most individuals who develop NMSCs, and the efficacy of T4N5 has not yet been determined in DNA repair-proficient individuals.
Photolyase is an enzyme derived from the algae Anacystis nidulans. Following activation by visible light, photolyase unlinks CPDs and 6-4 pyrimidine pyrimidone photoproducts, restoring them to their native conformation (Li et al., 2010) . Application to UVB-irradiated skin in vivo in a liposomal preparation followed by activation with photoreactivating light also led to a reduction in CPDs (Stege et al., 2000) .
In this issue, Johnson et al. report a novel enzyme that enhances the repair of UV-damaged DNA: pyrimidine dimer glycosylase, expressed by the Chlorella virus (Cv-pdg). Because the enzyme localizes primarily in the cytoplasm rather than in the nucleus and because it would not be expected to penetrate through the stratum corneum when applied topically, the invest igators incorporated a nuclear localization signaling sequence (NLS) and a membrane permeabilization peptide (TAT) into the molecule. The modified enzyme is particularly interesting because the engineered structure allows for its effective penetration through the top layers of the skin without the need for encapsulation into a delivery vehicle. Cv-pdg contributes to BER in prokaryotic species and is similar to the one lacking in human cells. In the study, Cv-pdg-NLS-TAT was applied topically to human skin equivalents. The engineered enzyme was absorbed and reached the basal layer of the epidermal equivalent. There, it localized in the nucleus and was found to be effective at diminishing a high percentage of CPDs when administered either before or after exposure to UVR.
These findings suggest that Cv-pdg-NLS-TAT may have both cancer preventive and therapeutic applications and therefore could be ideal for individuals at high risk for NMSCs, such as patients with XP, organ transplant recipients, and individuals with extensive photodamage. However, evidence of clinical efficacy and tolerability for Cv-pdg-NLS-TAT awaits clinical trials. That Cv-pdg-NLS-TAT did not require encapsulation into a delivery vehicle to reach basal keratinocytes is an advantage over both T4N5 and photolyase. The Cv-pdg-NLS-TAT topical enzyme also is more stable over a range of salt concentrations and temperature extremes than other topical formulations that accelerate the repair of UV-damaged DNA (McCullough, 1998) . Furthermore, Cv-pdg-NLS-TAT showed favorable retention kinetics in skin cells, indicating that it may be ideal for developing a convenient dosing regimen for human application.
Although mutations in the Sonic hedgehog pathway (for BCCs) and in p53 (for both BCCs and SCCs) are responsible for most NMSCs, some of those tumors lack these mutations (Athar et al., 2006) . Because Cv-pdg-NLS-TAT is able to repair a broad range of DNA mutations, Johnson et al. (2011) postulate it could have broad efficacy against a variety of UV-induced mutations and, in contrast to other potential chemopreventive agents (Hacker et al., 2010) , may be effective for the small number of UV-induced tumors without CPDs. Cv-pdg-NLS-TAT may also be useful in melanoma prevention because it has broad substrate specificity and an improved nuclear concentration caused by the NLS component.
Even if Cv-pdg-NLS-TAT is found to be effective, additional properties remain to be evaluated for it to be acceptable for widespread application in humans, including examination of its irritancy following chronic application and its cosmetic elegance.
Another important issue is the effect of this enzyme on the repair of oxidative DNA lesions induced by the reactive oxygen species that arise following UV exposure. UVB and UVA radiation can lead to oxidative DNA damage, such as 8-hydroxyguanisine, which is mutagenic and may contribute to the development of skin cancers (Kunisada et al., 2005;  Clinical Implications
• Cv-pdg-NLS-TAT is a genetically engineered glycosylase that enables human skin to perform base excision repair of UVR-damaged DNA.
• In contrast to other topically applied enzymes, Cv-pdg-NLS-TAT has greater nuclear localization, can penetrate into the lower levels of the epidermis without encapsulation into a delivery vehicle, is more stable, and may act against a wider variety of UVR-induced mutations.
• Cv-pdg-NLS-TAT shows promise as a topical preventive and therapeutic agent for patients at high risk for UVR-induced skin cancer. et al., 2007) . It would be interesting and important to determine whether Cv-pdg-NLS-TAT repaired this type of DNA damage as well. This enzyme may not have a direct effect on the repair of oxidative DNA damage, but it may contribute to an overall upregulation of repair mechanisms in the nuclear environment.
Montaner
Because NMSCs continue to be a major health and economic issue, the development of new treatment and preventive modalities is crucial. In addition to standard recommendations such as sun avoidance and the application of sunscreen, there are promising treatments and preventive therapies on the horizon. Cv-pdg-NLS-TAT may be one such modality; future clinical studies will further define its efficacy and tolerability.
